Humacyte Stock Surges 5.75% Amid Mixed Analyst Ratings Humacyte Inc. saw a 5.75% rise in its stock price today, closing at $3.31. Despite this gain, short-term and long-term indicators suggest a "Sell" rating. Analysts remain divided, with ratings ranging from "Hold" to "Buy," and an average price target of $8. Investors are eyeing its recent FDA-approved product launch.12